[Multicenter investigation of preventive measures against FOLFOX-induced neurotoxicity-a project of the 4th Chapter of the Oncology Research Group, Aichi Prefectural Society of Hospital Pharmacists].
FOLFOX therapy is associated with a high incidence of neurotoxicity that is specific to oxaliplatin and liable to lead to marked deterioration in the patient's quality of life (QOL). Therefore, we conducted a survey on whether any prophylactic measures were taken to guard against the development of such neurotoxicity, and we investigated the incidence of the neurotoxicity and the efficacy of glutathione and Ca/Mg administration. The results of the survey indicated that 5 among 17 medical facilities engaged in prophylactic measures. The timing of the initial development of neurotoxicity was after 2.9 courses of FOLFOX therapy for those without prophylaxis, after 7.5 courses for those treated with glutathione, and 6.4 courses for those on Ca/Mg treatment. The glutathione or Ca/Mg treatment significantly delayed development of the neurotoxicity. The mean total number of cycles that had been given by the completion of FOLFOX therapy was 5, 9, 11.3 and 8.5, respectively, for no prophylactic treatment, treatment with glutathione and Ca/Mg, indicating that these prophylactic measures allow increases in the number of cycles of FOLFOX therapy given. It was concluded that glutathione or Ca/Mg administered with FOLFOX therapy can delay the development of neurotoxicity, thus contributing to an improvement in the patient's QOL.
Sakakibara
Takashi
T
The 4th Chapter of the Oncology Research Group of Aichi Prefectural Society of Hospital Pharmacists.
Matsuyoshi
Koji
K
Yuki
Kanematsu
K
Yokota
Manabu
M
Itakura
Yukari
Y
Adachi
Mamoru
M
Saito
Hiroko
H
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005472:Fluorouracil